Use of NK-1 receptor antagonists for treating bipolar disorders
申请人:Merck Sharp & Dohme Ltd.
公开号:US05977104A1
公开(公告)日:1999-11-02
The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.